GLP-1 prescriptions for kids up more than 30,000% since 2019
Prescriptions for GLP-1 medications among children in the United States have surged by over 30,000% since 2019.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
GLP-1 prescriptions for children increased by more than 30,000 percent since 2019. Use spiked among teens and young adults as bariatric surgery declined, while use among young children with obesity remained rare but rose rapidly.
Epilogue added 67d ago, after coverage quieted.
The brief
Medical data indicates a massive increase in the prescription of GLP-1 medications for children in the United States. According to reports from WATE 6 On Your Side and newsnationnow.com, the number of these prescriptions for kids has risen by more than 30,000% since 2019. This trend highlights a significant shift in how obesity is being managed in pediatric populations across the country. While the percentage increase is substantial, the scale of the rollout varies by age group, with specific focus on those struggling with obesity. Coverage from NYU Langone Health emphasizes that despite this rapid rise, the actual use of GLP-1 medications among young children with obesity remains rare.
The report from NYU Langone Health notes that while the growth is occurring quickly, it has not yet become a common practice for the youngest pediatric patients. WATE 6 On Your Side and newsnationnow.com both focused their reporting on the specific statistical jump of 30,000% since the 2019 benchmark, highlighting the acceleration of these prescriptions. This trend emerges as a response to pediatric obesity, creating a new landscape for childhood medical treatment. The context provided by the reporting suggests that these medications, which were previously less common for minors, are now being utilized at a rate that far exceeds previous years. This matters because the rapid adoption of GLP-1s represents a fundamental change in the clinical approach to treating obesity in the youth population, moving toward pharmacological interventions more frequently than in the past.
Future developments will likely center on whether the use of GLP-1s among young children continues to rise from its current rare status. Because NYU Langone Health characterized the current use in young children as still being uncommon, observers will be monitoring if the growth rate seen since 2019 persists. The data established by newsnationnow.com and WATE 6 On Your Side provides a baseline for evaluating the long-term trajectory of these prescriptions in the US healthcare system.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 69d ago.
Quick answers
By how much have GLP-1 prescriptions for kids increased since 2019?
They have increased by more than 30,000%.
Is GLP-1 use common among very young children?
According to NYU Langone Health, use among young children with obesity remains rare, although it is rising rapidly.
Which outlets reported on this trend?
The trend was reported by NYU Langone Health, WATE 6 On Your Side, and newsnationnow.com.
Coverage (5)
- GLP-1 prescriptions for kids up more than 30,000 percent since 2019 The Hill · 69d ago
- GLP-1 use spiking among teens, young adults amid ‘steep’ decline in bariatric surgery Healio · 70d ago
- GLP-1 Use Among Young Children With Obesity in US Remains Rare but Is Rising Rapidly NYU Langone Health · 70d ago
- GLP-1 prescriptions for children up more than 30,000% since 2019 WATE 6 On Your Side · 70d ago
- GLP-1 prescriptions for kids up more than 30,000% since 2019 newsnationnow.com · 70d ago
Topics
Related trends
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Hundreds of children in England prescribed weight-loss jabs, figures show
New figures reveal hundreds of children in England, including under-12s, have been prescribed weight-loss jabs.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.